324 related articles for article (PubMed ID: 34936067)
21. Ocular drug delivery.
Goepferich A
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):157. PubMed ID: 26004820
[No Abstract] [Full Text] [Related]
22. Non-invasive strategies for targeting the posterior segment of eye.
Madni A; Rahem MA; Tahir N; Sarfraz M; Jabar A; Rehman M; Kashif PM; Badshah SF; Khan KU; Santos HA
Int J Pharm; 2017 Sep; 530(1-2):326-345. PubMed ID: 28755994
[TBL] [Abstract][Full Text] [Related]
23. Topical application of polymeric nanomicelles in ophthalmology: a review on research efforts for the noninvasive delivery of ocular therapeutics.
Grimaudo MA; Pescina S; Padula C; Santi P; Concheiro A; Alvarez-Lorenzo C; Nicoli S
Expert Opin Drug Deliv; 2019 Apr; 16(4):397-413. PubMed ID: 30889977
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in ophthalmic preparations: Ocular barriers, dosage forms and routes of administration.
Maulvi FA; Shetty KH; Desai DT; Shah DO; Willcox MDP
Int J Pharm; 2021 Oct; 608():121105. PubMed ID: 34537269
[TBL] [Abstract][Full Text] [Related]
25. Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases.
Durgun ME; Güngör S; Özsoy Y
J Ocul Pharmacol Ther; 2020; 36(6):323-341. PubMed ID: 32310723
[TBL] [Abstract][Full Text] [Related]
26. Fundamentals, challenges, and nanomedicine-based solutions for ocular diseases.
Srinivasarao DA; Lohiya G; Katti DS
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jul; 11(4):e1548. PubMed ID: 30506871
[TBL] [Abstract][Full Text] [Related]
27. Electrospun nanofibers - A promising solid in-situ gelling alternative for ocular drug delivery.
Göttel B; de Souza E Silva JM; Santos de Oliveira C; Syrowatka F; Fiorentzis M; Viestenz A; Viestenz A; Mäder K
Eur J Pharm Biopharm; 2020 Jan; 146():125-132. PubMed ID: 31816391
[TBL] [Abstract][Full Text] [Related]
28. Ophthalmic drug delivery considerations at the cellular level: drug-metabolising enzymes and transporters.
Attar M; Shen J; Ling KH; Tang-Liu D
Expert Opin Drug Deliv; 2005 Sep; 2(5):891-908. PubMed ID: 16296785
[TBL] [Abstract][Full Text] [Related]
29. Ocular delivery systems for topical application of anti-infective agents.
Duxfield L; Sultana R; Wang R; Englebretsen V; Deo S; Rupenthal ID; Al-Kassas R
Drug Dev Ind Pharm; 2016 Jan; 42(1):1-11. PubMed ID: 26325119
[TBL] [Abstract][Full Text] [Related]
30. Ophthalmic drug dosage forms: characterisation and research methods.
Baranowski P; Karolewicz B; Gajda M; Pluta J
ScientificWorldJournal; 2014; 2014():861904. PubMed ID: 24772038
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in topical nano drug-delivery systems for the anterior ocular segment.
Lakhani P; Patil A; Majumdar S
Ther Deliv; 2018 Feb; 9(2):137-153. PubMed ID: 29325511
[TBL] [Abstract][Full Text] [Related]
32. Dendrimers as a promising tool in ocular therapeutics: Latest advances and perspectives.
Rodríguez Villanueva J; Navarro MG; Rodríguez Villanueva L
Int J Pharm; 2016 Sep; 511(1):359-366. PubMed ID: 27436708
[TBL] [Abstract][Full Text] [Related]
33. Hyaluronic acid in ocular drug delivery.
Zhang X; Wei D; Xu Y; Zhu Q
Carbohydr Polym; 2021 Jul; 264():118006. PubMed ID: 33910737
[TBL] [Abstract][Full Text] [Related]
34. Modern drug delivery systems for targeting the posterior segment of the eye.
Peptu CA; Popa M; Savin C; Popa RF; Ochiuz L
Curr Pharm Des; 2015; 21(42):6055-69. PubMed ID: 26503152
[TBL] [Abstract][Full Text] [Related]
35. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases.
Choonara YE; Pillay V; Danckwerts MP; Carmichael TR; du Toit LC
J Pharm Sci; 2010 May; 99(5):2219-39. PubMed ID: 19894268
[TBL] [Abstract][Full Text] [Related]
36. Iontophoresis: a non-invasive ocular drug delivery.
Eljarrat-Binstock E; Domb AJ
J Control Release; 2006 Feb; 110(3):479-89. PubMed ID: 16343678
[TBL] [Abstract][Full Text] [Related]
37. Dendrimer nanoparticles for ocular drug delivery.
Kambhampati SP; Kannan RM
J Ocul Pharmacol Ther; 2013 Mar; 29(2):151-65. PubMed ID: 23410062
[TBL] [Abstract][Full Text] [Related]
38. Ocular novel drug delivery: impacts of membranes and barriers.
Barar J; Javadzadeh AR; Omidi Y
Expert Opin Drug Deliv; 2008 May; 5(5):567-81. PubMed ID: 18491982
[TBL] [Abstract][Full Text] [Related]
39. The prominence of the dosage form design to treat ocular diseases.
Campos PM; Petrilli R; Lopez RFV
Int J Pharm; 2020 Aug; 586():119577. PubMed ID: 32622806
[TBL] [Abstract][Full Text] [Related]
40. Advances in ocular drug delivery.
Rawas-Qalaji M; Williams CA
Curr Eye Res; 2012 May; 37(5):345-56. PubMed ID: 22510004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
